Detail analýzy
| 08.09.2023 / Erste Group Research |
Základní informace
| Autor | Erste Group Research |
| Datum | 08.09.2023 |
| Jazyk |  |
| Název produktu | Recommendation List |
| Hlavní téma | Akcie |
| Zaostřeno na ekonomiku | Japonsko, Německo, Spojené Státy |
| Zaměřeno na měnu | Americký dolar, Euro |
| Zaměřeno na sektor | Automobilový průmysl, Banky, Cestování a volný čas, Chemický průmysl, Finanční služby, Jídlo a nápoje, Maloobchodní prodej, Média, Pojišťovnictví, Průmyslové zboží a služby, Ropa & plyn, Síťová odvětví, Stavebnictví a materiály, Technologie, Telekomunikace, Základní materiály, Zboží osobní spotřeby, Zdravotnictví |
| Stáhnout |
Související investiční nástroje
Strana 1 z 6
| Název | ISIN | |
| ABB | CH0012221716 | 0 |
| Abbott Laboratories | US0028241000 | 0 |
| AbbVie | US00287Y1091 | 0 |
| Adidas | DE000A1EWWW0 | 3 |
| Adobe | US00724F1012 | 0 |
| Advanced Micro Devices | US0079031078 | 0 |
| Alibaba | US01609W1027 | 0 |
| Allianz | DE0008404005 | 0 |
| Alphabet | US02079K3059 | 0 |
| Amadeus IT Group | ES0109067019 | 0 |
| Amazon.Com | US0231351067 | 0 |
| AmBev | BRABEVACNOR1 | 0 |
| Amgen | US0311621009 | 0 |
| Anheuser Busch Inbev | BE0974293251 | 0 |
| Apple | US0378331005 | 0 |
| ASML | NL0010273215 | 0 |
| AT&T | US00206R1023 | 0 |
| Banco Santander | ES0113900J37 | 0 |
| Bank of America | US0605051046 | 0 |
| BASF | DE000BASF111 | 2 |
| Bayer | DE000BAY0017 | 0 |
| Beiersdorf | DE0005200000 | 0 |
| BHP Group | GB00BH0P3Z91 | 0 |
| BMW | DE0005190003 | 3 |
| BNP Paribas | FR0000131104 | 0 |
Healthcare sector with +12% earnings growth in 2024e Rating changes: SAP, Banco Santander, Novartis, ConocoPhillips, S&P Global, Nike, Taiwan Semiconductor, AstraZeneca, Amadeus IT Group, Moncler As the 2Q23 reporting season draws to a close, investor focus is increasingly turning to 2024 earnings expectations, where growth is forecast to accelerate in both revenue and earnings. Calculated in USD, sales growth should accelerate to +3.7% y/y (23e: +0.6%). The earnings forecast for the world's 1000 largest stocks has also improved slightly recently. In the coming year, the expected increase is +8.5% y/y (23e: +4.2%). In the healthcare sector, which we continue to favor, earnings growth of +12% Y/Y is forecast for 2024. The expected growth rate is thus significantly above that of the overall market. Novartis convinces us by the recently implemented business policy measures and due to an attractive valuation. SAP: Further revenue growth potential through AI integration in applications S&P Global: Leading financial services provider increases free cash flow very strongly this year |
 Stáhnout PDF (8,5MB)
|